当前位置: 首页 > 详情页

IL-21 promotes myocardial ischaemia/reperfusion injury through the modulation of neutrophil infiltration

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Cardiology, Union Hospital, TongjiMedical College, Huazhong University of Science and Technology,Wuhan, China, [2]Key Laboratory of Biological Targeted Therapy of EducationMinistry and Hubei Province, Union Hospital, TongjiMedical College, Huazhong University of Science and Technology, Wuhan, China, [3]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, [4]Key Laboratory of Molecular Biophysics of the Ministry of Education, Cardio-X Institute, College of Life Science and Technology and Center of Human Genome Research, Huazhong University of Science and Technology, Wuhan, China, [5]Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
出处:
ISSN:

摘要:
Background and PurposeThe immune system plays an important role in driving the acute inflammatory response following myocardial ischaemia/reperfusion injury (MIRI). IL-21 is a pleiotropic cytokine with multiple immunomodulatory effects, but its role in MIRI is not known. Experimental ApproachMyocardial injury, neutrophil infiltration and the expression of neutrophil chemokines KC (CXCL1) and MIP-2 (CXCL2) were studied in a mouse model of MIRI. Effects of IL-21 on the expression of KC and MIP-2 in neonatal mouse cardiomyocytes (CMs) and cardiac fibroblasts (CFs) were determined by real-time PCR and ELISA. The signalling mechanisms underlying these effects were explored by western blot analysis. Key ResultsIL-21 was elevated within the acute phase of murine MIRI. Neutralization of IL-21 attenuated myocardial injury, as illustrated by reduced infarct size, decreased cardiac troponin T levels and improved cardiac function, whereas exogenous IL-21 administration exerted opposite effects. IL-21 increased the infiltration of neutrophils and increased the expression of KC and MIP-2 in myocardial tissue following MIRI. Moreover, neutrophil depletion attenuated the IL-21-induced myocardial injury. Mechanistically, IL-21 increased the production of KC and MIP-2 in neonatal CMs and CFs, and enhanced neutrophil migration, as revealed by the migration assay. Furthermore, we demonstrated that this IL-21-mediated increase in chemokine expression involved the activation of Akt/NF-B signalling in CMs and p38 MAPK/NF-B signalling in CFs. Conclusions and ImplicationsOur data provide novel evidence that IL-21 plays a pathogenic role in MIRI, most likely by promoting cardiac neutrophil infiltration. Therefore, targeting IL-21 may have therapeutic potential as a treatment for MIRI. Linked ArticlesThis article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 1 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2016]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Cardiology, Union Hospital, TongjiMedical College, Huazhong University of Science and Technology,Wuhan, China, [2]Key Laboratory of Biological Targeted Therapy of EducationMinistry and Hubei Province, Union Hospital, TongjiMedical College, Huazhong University of Science and Technology, Wuhan, China,
共同第一作者:
通讯作者:
通讯机构: [1]Department of Cardiology, Union Hospital, TongjiMedical College, Huazhong University of Science and Technology,Wuhan, China, [2]Key Laboratory of Biological Targeted Therapy of EducationMinistry and Hubei Province, Union Hospital, TongjiMedical College, Huazhong University of Science and Technology, Wuhan, China, [*1]Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院